CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
Charlotte, North Carolina, United States and 25 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Charlotte, North Carolina, United States and 145 other locations
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...
Phase 1
Charlotte, North Carolina, United States and 13 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Charlotte, North Carolina, United States and 40 other locations
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...
Phase 1, Phase 2
Charlotte, North Carolina, United States and 13 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Charlotte, North Carolina, United States and 211 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Charlotte, North Carolina, United States and 126 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Charlotte, North Carolina, United States and 46 other locations
of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...
Phase 1
Charlotte, North Carolina, United States and 17 other locations
and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options...
Phase 1
Charlotte, North Carolina, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal